Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
K. Püschel,
S. Kluge,
M. M. Addo and
M. Aepfelbacher,
"Von den Toten lernen - neue Erkenntnisse zu Covid-19",
Hamburger Ärzteblatt,
vol. 74,
no. 06/2020,
pp. 34—36,
Jun.
2020.
| Datei: | https://fis-uke.de/portal/de/publications/von-den-toten-lernen—neue-erkenntnisse-zu-covid19(fd7b5c64-a609-4b09-9654-a83695f66e7b).html |
F. Ramsthaler,
S. Heinbuch,
P. H. Schmidt,
R. M. Bohle,
J. Rissland,
B. Gärtner,
M. A. Verhoff,
M. Kettner and
S. Potente,
"Aktuelle Empfehlungen zum Umgang mit dem Verdacht auf COVID-19 in der rechtsmedizinischen Routine",
Archiv für Kriminologie,
vol. 245,
pp. 50-63,
Mä.
2020.
| Datei: |  https://www.archivfuerkriminologie.de/uploads/JSrJ2YzH/ArbeitRamsthaleretal_ArchKrimBand24534.pdf |
A. Ron and
K. Püschel,
"Todesursachen im Zusammenhang mit Infektionen durch SARS-CoV-2",
WUNDmanagement,
vol. 14,
no. 3/2020,
pp. 133-135,
Mä.
2020.
| Datei: | https://www.uke.de/dateien/einrichtungen/medizinische-fakult%C3%A4t/forschung/todesursachen_corona-wundmanagement_p%C3%BCschel-2020.pdf |
V. Dao Thi,
K. Herbst,
K. Börner and
D. Stahl,
"A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples",
Science Translational Medicine,
vol. 12,
no. 556,
2020.
| DOI: | 10.1126/scitranslmed.abc7075 |
| Datei: | https://doi.org/10.1126/scitranslmed.abc7075 |
[German]
P. Boor and
A. Hartmann,
"Bericht zur Late-Breaking Session Pathologie und COVID-19 [Late Breaking Session Pathology and COVID-19 Report]",
Pathologe,
vol. 41,
no. Suppl 2,
pp. 96-98,
2020.
| DOI: | 10.1007/s00292-020-00882-w |
P. Fervers,
J. Kottlors,
D. Zopfs,
J. Bremm,
D. Maintz,
O. Safarov,
S. Tritt,
N. Abdullayev and
T. Persigehl,
"Calcification of the thoracic aorta on low-dose chest CT predicts severe COVID-19",
PloS one,
vol. 15,
no. 12,
pp. e0244267,
2020.
Abstract:
Cardiovascular comorbidity anticipates poor prognosis of SARS-CoV-2 disease (COVID-19) and correlates with the systemic atherosclerotic transformation of the arterial vessels. The amount of aortic wall calcification (AWC) can be estimated on low-dose chest CT. We suggest quantification of AWC on the low-dose chest CT, which is initially performed for the diagnosis of COVID-19, to screen for patients at risk of severe COVID-19. Seventy consecutive patients (46 in center 1, 24 in center 2) with parallel low-dose chest CT and positive RT-PCR for SARS-CoV-2 were included in our multi-center, multi-vendor study. The outcome was rated moderate (no hospitalization, hospitalization) and severe (ICU, tracheal intubation, death), the latter implying a requirement for intensive care treatment. The amount of AWC was quantified with the CT vendor's software. Of 70 included patients, 38 developed a moderate, and 32 a severe COVID-19. The average volume of AWC was significantly higher throughout the subgroup with severe COVID-19, when compared to moderate cases (771.7 mm3 (Q1 = 49.8 mm3, Q3 = 3065.5 mm3) vs. 0 mm3 (Q1 = 0 mm3, Q3 = 57.3 mm3)). Within multivariate regression analysis, including AWC, patient age and sex, as well as a cardiovascular comorbidity score, the volume of AWC was the only significant regressor for severe COVID-19 (p = 0.004). For AWC > 3000 mm3, the logistic regression predicts risk for a severe progression of 0.78. If there are no visually detectable AWC risk for severe progression is 0.13, only. AWC seems to be an independent biomarker for the prediction of severe progression and intensive care treatment of COVID-19 already at the time of patient admission to the hospital; verification in a larger multi-center, multi-vendor study is desired.
| DOI: | 10.1371/journal.pone.0244267 |
| Datei: | https://pubmed.ncbi.nlm.nih.gov/33362199/ |
Abstract:
Cardiovascular comorbidity anticipates poor prognosis of SARS-CoV-2 disease (COVID-19) and correlates with the systemic atherosclerotic transformation of the arterial vessels. The amount of aortic wall calcification (AWC) can be estimated on low-dose chest CT. We suggest quantification of AWC on the low-dose chest CT, which is initially performed for the diagnosis of COVID-19, to screen for patients at risk of severe COVID-19. Seventy consecutive patients (46 in center 1, 24 in center 2) with parallel low-dose chest CT and positive RT-PCR for SARS-CoV-2 were included in our multi-center, multi-vendor study. The outcome was rated moderate (no hospitalization, hospitalization) and severe (ICU, tracheal intubation, death), the latter implying a requirement for intensive care treatment. The amount of AWC was quantified with the CT vendor's software. Of 70 included patients, 38 developed a moderate, and 32 a severe COVID-19. The average volume of AWC was significantly higher throughout the subgroup with severe COVID-19, when compared to moderate cases (771.7 mm3 (Q1 = 49.8 mm3, Q3 = 3065.5 mm3) vs. 0 mm3 (Q1 = 0 mm3, Q3 = 57.3 mm3)). Within multivariate regression analysis, including AWC, patient age and sex, as well as a cardiovascular comorbidity score, the volume of AWC was the only significant regressor for severe COVID-19 (p = 0.004). For AWC > 3000 mm3, the logistic regression predicts risk for a severe progression of 0.78. If there are no visually detectable AWC risk for severe progression is 0.13, only. AWC seems to be an independent biomarker for the prediction of severe progression and intensive care treatment of COVID-19 already at the time of patient admission to the hospital; verification in a larger multi-center, multi-vendor study is desired.
J. Meerpohl,
S. Voigt-Radloff,
G. Rueschemeyer,
F. Balzer,
C. Benstoem,
H. Binder,
M. Boeker,
J. Burns,
U. Dirnagl,
R. Featherstone,
F. Fichtner,
H. Grundmann,
H. Hengel,
V. Kempf,
W. Kern,
P. Kranke,
S. Laudi,
S. Lieb,
A. Maun,
C. Mavergames,
M. I. Metzendorf,
M. Nothacker,
C. Schmaderer,
C. Schmucker,
L. Schwingshackl,
N. Skoetz,
A. Steckelberg,
M. Stegemann,
D. Strech,
O. Moerer,
E. Rehfuess and
C. Spies,
"CEOsys: Creating an ecosystem for COVID-19 evidence In: Collaborating in response to COVID-19: editorial and methods initiatives across Cochrane",
Cochrane Database of Systematic Reviews,
vol. 12,
no. Suppl 1,
2020.
| DOI: | 10.1002/14651858.CD202002 |
D. Gagiannis,
J. Steinestel,
C. Hackenbroch,
B. Schreiner,
M. Hannemann,
W. Bloch,
V. G. Umathum,
N. Gebauer,
C. Rother,
M. Stahl and
D. Stahl,
"Clinical, Serological, and Histopathological Similarities Between Severe COVID-19 and Acute Exacerbation of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)",
Front Immunol,
vol. 11,
pp. 587517,
2020.
| DOI: | 10.3389/fimmu.2020.587517 |
S. Meiler,
O. W. Hamer,
J. Schaible,
F. Zeman,
N. Zorger,
H. Kleine,
J. Rennert,
C. Stroszczynski and
F. Poschenrieder,
"Computed tomography characterization and outcome evaluation of COVID-19 pneumonia complicated by venous thromboembolism",
PloS one,
vol. 15,
no. 11,
pp. e0242475,
2020.
Abstract:
COVID-19 is frequently complicated by venous thromboembolism (VTE). Computed tomography (CT) of the chest-primarily usually conducted as low-dose, non-contrast enhanced CT-plays an important role in the diagnosis and follow-up of COVID-19 pneumonia. Performed as contrast-enhanced CT pulmonary angiography, it can reliably detect or rule-out pulmonary embolism (PE). Several imaging characteristics of COVID-19 pneumonia have been described for chest CT, but no study evaluated CT findings in the context of VTE/PE. In our retrospective study, we analyzed clinical, laboratory and CT imaging characteristics of 50 consecutive patients with RT-PCR proven COVID-19 pneumonia who underwent contrast-enhanced chest CT at two tertiary care medical centers. All patients with RT-PCR proven COVID-19 pneumonia and contrast-enhanced chest CT performed at two tertiary care hospitals between March 1st and April 20th 2020 were retrospectively identified. Patient characteristics (age, gender, comorbidities), symptoms, date of symptom onset, RT-PCR results, imaging results of CT and leg ultrasound, laboratory findings (C-reactive protein, differential blood count, troponine, N-terminal pro-B-type natriuretic peptide (NT-proBNP), fibrinogen, interleukin-6, D-dimer, lactate dehydrogenase (LDH), creatine kinase (CK), creatine kinase muscle-brain (CKmb) and lactate,) and patient outcome (positive: discharge or treatment on normal ward; negative: treatment on intensive care unit (ICU), need for mechanical ventilation, extracorporeal membrane oxygenation (ECMO), or death) were analyzed. Follow-up was performed until May 10th. Patients were assigned to two groups according to two endpoints: venous thromboembolism (VTE) or no VTE. For statistical analysis, univariate logistic regression models were calculated. This study includes 50 patients. In 14 out of 50 patients (28%), pulmonary embolism was detected at contrast-enhanced chest CT. The majority of PE was detected on CTs performed on day 11-20 after symptom onset. Two patients (14%) with PE simultaneously had evidence of deep vein thrombosis. 15 patients (30%) had a negative outcome (need for intensive care, mechanical ventilation, extracorporeal membrane oxygenation, or death), and 35 patients (70%) had a positive outcome (transfer to regular ward, or discharge). Patients suffering VTE had a statistically significant higher risk of an unfavorable outcome (p = 0.028). In univariate analysis, two imaging characteristics on chest CT were associated with VTE: crazy paving pattern (p = 0.024) and air bronchogram (n = 0.021). Also, elevated levels of NT-pro BNP (p = 0.043), CK (p = 0.023) and D-dimers (p = 0.035) were significantly correlated with VTE. COVID-19 pneumonia is frequently complicated by pulmonary embolism (incidence of 28% in our cohort), remarkably with lacking evidence of deep vein thrombosis in nearly all thus affected patients of our cohort. As patients suffering VTE had an adverse outcome, we call for a high level of alertness for PE and advocate a lower threshold for contrast-enhanced CT in COVID-19 pneumonia. According to our observations, this might be particularly justified in the second week of disease and if a crazy paving pattern and / or air bronchogram is present on previous non-enhanced CT.
| DOI: | 10.1371/journal.pone.0242475 |
| Datei: | https://pubmed.ncbi.nlm.nih.gov/33211737/ |
Abstract:
COVID-19 is frequently complicated by venous thromboembolism (VTE). Computed tomography (CT) of the chest-primarily usually conducted as low-dose, non-contrast enhanced CT-plays an important role in the diagnosis and follow-up of COVID-19 pneumonia. Performed as contrast-enhanced CT pulmonary angiography, it can reliably detect or rule-out pulmonary embolism (PE). Several imaging characteristics of COVID-19 pneumonia have been described for chest CT, but no study evaluated CT findings in the context of VTE/PE. In our retrospective study, we analyzed clinical, laboratory and CT imaging characteristics of 50 consecutive patients with RT-PCR proven COVID-19 pneumonia who underwent contrast-enhanced chest CT at two tertiary care medical centers. All patients with RT-PCR proven COVID-19 pneumonia and contrast-enhanced chest CT performed at two tertiary care hospitals between March 1st and April 20th 2020 were retrospectively identified. Patient characteristics (age, gender, comorbidities), symptoms, date of symptom onset, RT-PCR results, imaging results of CT and leg ultrasound, laboratory findings (C-reactive protein, differential blood count, troponine, N-terminal pro-B-type natriuretic peptide (NT-proBNP), fibrinogen, interleukin-6, D-dimer, lactate dehydrogenase (LDH), creatine kinase (CK), creatine kinase muscle-brain (CKmb) and lactate,) and patient outcome (positive: discharge or treatment on normal ward; negative: treatment on intensive care unit (ICU), need for mechanical ventilation, extracorporeal membrane oxygenation (ECMO), or death) were analyzed. Follow-up was performed until May 10th. Patients were assigned to two groups according to two endpoints: venous thromboembolism (VTE) or no VTE. For statistical analysis, univariate logistic regression models were calculated. This study includes 50 patients. In 14 out of 50 patients (28%), pulmonary embolism was detected at contrast-enhanced chest CT. The majority of PE was detected on CTs performed on day 11-20 after symptom onset. Two patients (14%) with PE simultaneously had evidence of deep vein thrombosis. 15 patients (30%) had a negative outcome (need for intensive care, mechanical ventilation, extracorporeal membrane oxygenation, or death), and 35 patients (70%) had a positive outcome (transfer to regular ward, or discharge). Patients suffering VTE had a statistically significant higher risk of an unfavorable outcome (p = 0.028). In univariate analysis, two imaging characteristics on chest CT were associated with VTE: crazy paving pattern (p = 0.024) and air bronchogram (n = 0.021). Also, elevated levels of NT-pro BNP (p = 0.043), CK (p = 0.023) and D-dimers (p = 0.035) were significantly correlated with VTE. COVID-19 pneumonia is frequently complicated by pulmonary embolism (incidence of 28% in our cohort), remarkably with lacking evidence of deep vein thrombosis in nearly all thus affected patients of our cohort. As patients suffering VTE had an adverse outcome, we call for a high level of alertness for PE and advocate a lower threshold for contrast-enhanced CT in COVID-19 pneumonia. According to our observations, this might be particularly justified in the second week of disease and if a crazy paving pattern and / or air bronchogram is present on previous non-enhanced CT.
A. Klein,
C. Edler,
A. Fitzek,
D. Fröb,
A. Heinemann,
K. Meißner,
H. Mushumba,
K. Püschel,
A. S. Schröder,
J. P. Sperhake,
F. Ishorst-Witte,
M. Aepfelbacher and
F. Heinrich,
"Der erste COVID-19-Hotspot in einer Hamburger Senioreneinrichtung: Präventionskonzept, Letalität und Obduktionsbefunde",
Rechtsmedizin,
vol. 30,
no. 5,
pp. 325—331,
2020.
M. Schrappe,
H. Francois-Kettner,
F. Knieps,
H. Pfaff,
K. Püschel and
G. Glaeske,
"Die Pandemie durch SARS-CoV-2/Covid-19 - der Übergang zur chronischen Phase",
Monitor Versorgungsforschung,
vol. 5,
pp. 35—68,
2020.
| Datei: | https://fis-uke.de/portal/de/publications/die-pandemie-durch-sarscov2covid19—der-ubergang-zur-chronischen-phase(329ee191-6357-4f08-8ea2-af048c3e45d8).html |
K. Subbarayan,
K. Ulagappan,
C. Wickenhauser and
B. Seliger,
"Expression and clinical significance of SARS-CoV-2 human targets in neoplastic and non-neoplastic lung tissues",
Curr Cancer Drug Targets,
2020.
| DOI: | 10.2174/1568009620666201207145019 |
S. Thun,
A. Bartschke,
J. Sass,
C. Kalle,
A. Essenwanger and
S. Rudolph,
"GECCO: Einigung Auf Datensatz Für COVID-19-Forschung",
EHEALTHCOM,
vol. 5,
pp. 14—17,
2020.
| Datei: | https://e-health-com.de/fileadmin/user_upload/dateien/ePaper/EHC_5_2020_ePaper.pdf |
A. Walker,
T. Houwaart,
T. Wienemann and
et al,
"Genetic structure of SARS-CoV-2 reflects clonal superspreading and multiple independent introduction events, North-Rhine Westphalia, Germany, February and March 2020",
Euro Surveillance,
vol. 25,
no. 22,
2020.
| DOI: | 10.2807/1560-7917.ES.2020.25.22.2000746 |
E. K. Broberg,
T. Connor and
et al,
"Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020",
Eurosurveillance,
vol. 25,
no. 32,
2020.
| DOI: | 10.2807/1560-7917.ES.2020.25.32.2001410 |
N. Pfeuffer,
G. Rohde and
O. Hinz,
"How and What Can Humans Learn from Being in the Loop?",
KI - Künstliche Intelligenz,
vol. 34,
no. 2,
pp. 199—207,
2020.
| DOI: | 10.1007/s13218-020-00638-x |
J. Schmitt,
L. Harst,
T. Weber,
M. Sedlmayr,
S. Ciesek,
C. Apfelbacher,
M. Bajbouj,
V. Bierbaum,
S. Combs,
C. Drosten,
M. Geraedts,
J. Haier,
P. Ihle,
K. Lieb,
G. Rohde,
H. Schmidberger,
C. Vogelmeier,
S. Weber-Carstens,
B. Weltermann and
M. Wagner,
"Konzept für ein bundesweites Pandemiemanagement im Rahmen des Netzwerks Universitätsmedizin",
German Medical Science GMS Publishing House,
2020.
| DOI: | 10.3205/20dkvf053 |
J. Bernardes,
N. Mishra,
F. Tran,
T. Bahmer,
L. Best,
J. Blase,
D. Bordoni,
J. Franzenburg,
U. Geisen,
J. Josephs-Spaulding and
D. Stahl,
"Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19",
Immunity,
vol. 53,
no. 6,
pp. 1296—1314.e9,
2020.
| DOI: | 10.1016/j.immuni.2020.11.017 |
P. Bacher and
et al,
"Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19",
Immunity,
vol. 53,
pp. 1258—1271.e5,
2020.
| DOI: | 10.1016/j.immuni.2020.11.016 |
S. Krishnaratne,
L. M. Pfadenhauer,
M. Coenen,
K. Geffert,
C. Jung-Sievers,
C. Klinger,
S. Kratzer,
H. Littlecott,
A. Movsisyan,
J. E. Rabe,
E. Rehfuess,
K. Sell,
B. Strahwald,
J. M. Stratil,
S. Voss,
K. Wabnitz and
J. Burns,
"Measures implemented in the school setting to contain the COVID-19 pandemic: a scoping review",
Cochrane Database Syst Rev,
vol. 12,
pp. CD013812,
2020.
| DOI: | 10.1002/14651858.CD013812 |
M. Wenzel,
F. K. H. Chun and
O. Hinz,
"Möglichkeiten einer automatisierten Auswertung der Thorax-Röntgenaufnahme durch künstliche Intelligenz für Klinik und Praxis",
Der Pneumologe,
vol. 17,
no. 1,
pp. 59—64,
2020.
| DOI: | 10.1007/s10405-019-00297-2 |
| Datei: | https://doi.org/10.1007/s10405-019-00297-2 |
M. Augustin,
P. Schommers,
I. Suárez and
et al,
"Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020",
Euro Surveill,
vol. 25,
no. 21,
2020.
| DOI: | 10.2807/1560-7917.ES.2020.25.21.2000531 |
S. Schneider,
B. Piening,
P. A. Nouri-Pasovsky and
et al,
"SARS-Coronavirus-2 cases in healthcare workers may not regularly originate from patient care: lessons from a university hospital on the underestimated risk of healthcare worker to healthcare worker transmission",
Antimicrob Resist Infect Control,
vol. 9,
no. 1,
2020.
| DOI: | 10.1186/s13756-020-00848-w |
D. Bojkova,
J. U. G. Wagner,
M. Shumliakivska,
G. S. Aslan,
U. Saleem,
A. Hansen,
G. Luxán,
S. Günther,
M. D. Pham,
J. Krishnan and
D. Stahl,
"SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes",
Cardiovasc Res,
vol. 116,
no. 14,
pp. 2207-2215,
2020.
| DOI: | 10.1093/cvr/cvaa267 |
S. Klein,
T. G. Müller,
D. Khalid and
et al,
"SARS-CoV-2 RNA extraction using magnetic beads for rapid large-scale testing by RT-qPCR and RT-LAMP",
Viruses,
vol. 12,
no. 8,
2020.
| DOI: | 10.3390/v12080863 |
| Datei: | https://doi.org/10.3390/v12080863 |
J. Schaible,
S. Meiler,
F. Poschenrieder,
G. Scharf,
F. Zeman,
J. Rennert,
B. Pregler,
C. Knobloch,
H. Kleine,
S. Grote,
C. Stroszczynski,
N. Zorger and
O. W. Hamer,
"Sharp margin and geographic shape: systematic evaluation of two novel CT features in COVID-19 pneumonia",
BJR open,
vol. 2,
no. 1,
pp. 20200026,
2020.
Abstract:
CT is important in the care of patients with COVID-19 pneumonia. However, specificity might be poor in the absence of a clinical and epidemiological context. The goal of this work was to systematically evaluate two novel CT features (sharp margin and geographic shape) of COVID-19 pneumonia. All patients with reverse transcription polymerase chain reaction proven COVID-19 pneumonia and chest CT between March first and April 15, 2020 were retrospectively identified from two tertiary care hospitals in Germany. The CTs were evaluated regarding the presence of typical CT signs (e.g. ground glass opacitiy, consolidation, crazy paving). Moreover, the shape of the opacifications (round, geographic, curvilinear) and their margin (unsharp, sharp) was determined. The study population comprised 108 patients (64 male) with a mean age of 59.6 years. Ground glass opacities (96%) and consolidation (75%) were the most prevalent CT signs. Crazy paving was seen in 17%, bronchial dilatation in 21%, air bronchogram in 29%, vessel enlargement in 47%, cavitation in 0%, lymphadenopathy in 32%, pleural effusion in 16%. Round configuration of densities was present in 41% of CTs, geographic shape in 27% and curvilinear opacities in 44%. 79% of opacifications were at least partially sharply marginated. In almost all cases, the lung was affected bilaterally (94%). The CT pattern of COVID-19 pneumonia in a cohort from Germany was in accordance with prior studies. However, we identified two novel CT signs of COVID-19 pneumonia which have so far not been systematically evaluated. A sharp border and geographic shape of opacifications were frequently observed. The newly described CT features "sharp margin" and "geographic shape" of opacifications in patients with COVID-19 pneumonia might help to increase specificity of CT.
| DOI: | 10.1259/bjro.20200026 |
| Datei: | https://pubmed.ncbi.nlm.nih.gov/33178983/ |
Abstract:
CT is important in the care of patients with COVID-19 pneumonia. However, specificity might be poor in the absence of a clinical and epidemiological context. The goal of this work was to systematically evaluate two novel CT features (sharp margin and geographic shape) of COVID-19 pneumonia. All patients with reverse transcription polymerase chain reaction proven COVID-19 pneumonia and chest CT between March first and April 15, 2020 were retrospectively identified from two tertiary care hospitals in Germany. The CTs were evaluated regarding the presence of typical CT signs (e.g. ground glass opacitiy, consolidation, crazy paving). Moreover, the shape of the opacifications (round, geographic, curvilinear) and their margin (unsharp, sharp) was determined. The study population comprised 108 patients (64 male) with a mean age of 59.6 years. Ground glass opacities (96%) and consolidation (75%) were the most prevalent CT signs. Crazy paving was seen in 17%, bronchial dilatation in 21%, air bronchogram in 29%, vessel enlargement in 47%, cavitation in 0%, lymphadenopathy in 32%, pleural effusion in 16%. Round configuration of densities was present in 41% of CTs, geographic shape in 27% and curvilinear opacities in 44%. 79% of opacifications were at least partially sharply marginated. In almost all cases, the lung was affected bilaterally (94%). The CT pattern of COVID-19 pneumonia in a cohort from Germany was in accordance with prior studies. However, we identified two novel CT signs of COVID-19 pneumonia which have so far not been systematically evaluated. A sharp border and geographic shape of opacifications were frequently observed. The newly described CT features "sharp margin" and "geographic shape" of opacifications in patients with COVID-19 pneumonia might help to increase specificity of CT.
A. Gruber,
N. Osterrieder,
L. Bertzbach,
D. Vladimirova,
S. Greuel and
e. a. Ihlow,
"Standardization of Reporting Criteria for Lung Pathology in SARS-CoV-2–infected Hamsters: What Matters?",
Am. J. Respir. Cell Mol. Biol.,
vol. 63,
pp. 856—859,
2020.
J. Erber,
V. Kappler,
B. Haller and
et al,
"Strategies for infection control and prevalence of anti-SARS-CoV-2 IgG in 4,554 employees of a university hospital in Munich, Germany",
MedRxiv,
2020.
| DOI: | 10.1101/2020.10.04.20206136 |
J. Sass,
A. Bartschke,
M. Lehne,
A. Essenwanger,
E. Rinaldi,
S. Rudolph,
K. Heitmann,
J. Vehreschild,
C. Kalle and
S. Thun,
"The German Corona Consensus Dataset (GECCO): a standardized dataset for COVID-19 research in university medicine and beyond",
BMC Med Inform Decis Mak,
vol. 20,
no. 1,
pp. 341,
2020.
| DOI: | 10.1186/s12911-020-01374-w |
M. Mayer,
L. Kunhan and
M. Zhu,
"China"
in Comparative Covid Response: Crisis, Knowledge, Politics, Jasanoff, S and et al., Eds.
2020.